Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

A Comparative In Vitro and In VivoPharmacological Characterization of the Novel Dopamine D3Receptor Antagonists (+)-S 14297, Nafadotride, GR 103,691 and U 99194

Valérie Audinot, Adrian Newman-Tancredi, Alain Gobert, Jean-Michel Rivet, Mauricette Brocco, Françoise Lejeune, Laurence Gluck, Isabelle Desposte, Karin Bervoets, Anne Dekeyne and Mark J. Millan
Journal of Pharmacology and Experimental Therapeutics October 1998, 287 (1) 187-197;
Valérie Audinot
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adrian Newman-Tancredi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alain Gobert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Michel Rivet
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mauricette Brocco
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Françoise Lejeune
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurence Gluck
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isabelle Desposte
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karin Bervoets
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Dekeyne
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark J. Millan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The benzofurane (+)-S 14297, the benzamide nafadotride, the aminoindane U 99194 and the arylpiperazine GR 103,691 have been proposed as “selective” antagonists at dopamine D3vs.D2 receptors. Herein, we compared their in vitroaffinities and in vivo actions to those of the aminotetralin D3 antagonists (+)-AJ 76 and (+)-UH 232. Affinities at recombinant, human (h)D3 and/or hD2 sites were determined by employing the mixed D2/D3antagonist [125I]-iodosulpride and the preferential D3 ligands [3H]-(+)-PD 128,907 and [3H]-(+)-S 14297. [3H]-(+)-PD 128,907, [3H]-(+)-S 14297 and [125I]-iodosulpride yielded an essentially identical pattern of displacement at D3 sites, which suggests that they recognize the same population of receptors. The rank order of potency (Ki values in nM vs.[3H]-(+)-PD 128,907) was GR 103,691 (0.4) ≈ nafadotride (0.5) > haloperidol (2) ≈ (+)-UH 232 (3) ≈ (+)-S 14297 (5) > (+)-AJ 76 (26) > U 99194 (160). The rank order of preference (Ki ratio, D2:D3) for D3 receptors (labeled by [3H]-PD 128,907)vs. D2 sites (labeled by [125I]-iodosulpride) was (+)-S 14297 (61) ≈ GR 103,691 (60) > U 99194 (14) > nafadotride (9) ≈ (+)-UH 232 (8) ≈ (+)-AJ 76 (6) > haloperidol (0.2). (+)-S 14297 and GR 103,691 also showed greater than 100-fold selectivity at dopamine hD3vs. hD4 and hD1 sites. However, GR 103,691 showed marked affinity for serotonin1A receptors (5.8 nM) and alpha-1 adrenoceptors (12.6 nM). In vivo, all antagonists except GR 103,691 prevented the induction of hypothermia by (+)-PD 128,907 (0.63 mg/kg s.c.) and a further preferential D3 agonist, (+)-7-OH-DPAT (0.16 mg/kg s.c.). On the other hand, haloperidol, (+)-AJ 76, (+)-UH 232 and nafadotride all induced catalepsy in rats, whereas (+)-S 14297, U 99194 and GR 103,691 were inactive. Haloperidol, (+)-AJ 76, (+)-UH 232, nafadotride and (weakly) U 99194 also enhanced prolactin secretion and striatal dopamine synthesis, whereas (+)-S 14297 and GR 103,691 were inactive. However, despite its high affinity at 5-HT1A receptors andalpha-1 adrenoceptors, both of which are present on raphe-localized serotonergic neurons, GR 103,691 (0.5 mg/kg i.v.) failed to influence their basal firing rate or the inhibition of their electrical activity by the 5-HT1A agonist (±)-8-OH-DPAT (0.005 mg/kg i.v.), a result that casts doubt on its activity in vivo. In conclusion, both (+)-S 14297 and GR 103,691 are markedly selective ligands that permit the characterization of actions at hD3vs. hD2 receptors in vitro, but (+)-S 14297 appears to be of greater utility for the evaluation of their functional significance in vivo. Nevertheless, to develop a better understanding of the respective roles of dopamine D3 and D2 receptors, we need additional, chemically diverse antagonists of improved potency and selectivity.

DA is implicated in the modulation of several physiological functions, including endocrine secretion, motor behavior, thermoregulation and mood (Creese and Fraser, 1987). Its actions are expressedvia at least five different receptor types. On the basis of their molecular structure and pharmacological properties, these receptors have been divided into two families: D1-like, including D1 and D5 receptors, and D2-like, including D2, D3 and D4 receptors (Sokoloff and Schwartz, 1995; Strange, 1993). As concerns the D2 receptor family, the low level of expression of mRNA encoding D4 receptors in rodent and human tissue, and the hitherto lack of selective radioligands for D4 sites, have complicated the elucidation of their functional significance, although selective D4 antagonists are now becoming available (Boyfield et al., 1996; Bristowet al., 1997; Kulagowski et al., 1996; Merchantet al., 1996; Millan et al., 1996). In contrast, both in situ hybridization and polymerase chain reaction amplification studies have allowed for the localization of mRNA encoding D3 receptors in rodent and human brain, and the use of antibodies directed against D3 receptors has permitted localization of the corresponding protein (Bouthenet et al., 1991; Landwehrmeyer et al., 1993; Lévesqueet al., 1992). These approaches, together with studies of the preferential D3 agonists [3H]-(+)-PD 128,907 and [3H]-(+)-7-OH-DPAT (Hall et al., 1996; Herroelen et al., 1994), suggest that D3sites are predominantly localized in limbic regions such as the olfactory tubercles, the nucleus accumbens and the islands of Calleja. This restricted D3 receptor distribution contrasts with the broad distribution of D2 receptors (Gehlert et al., 1992; Larson and Ariano, 1995; Levant et al., 1993; Murray et al., 1994; Richtand et al., 1995). In addition, a minor population of D3 autoreceptors may exist with D2 autoreceptors on dopaminergic cell bodies of the ventral tegmental area and substantia nigra, pars compacta (Diazet al., 1995; Gobert et al., 1995; Koeltzowet al., 1998; Meador-Woodruff et al., 1996).

Despite the utility of gene knockout and antisense strategies (Acciliet al., 1996; Baik et al., 1995; Carta et al., 1996, Tepper et al., 1997), ligands that interact selectively with D3vs. D2 receptors are essential for an improved knowledge of their localization, modulation and functional significance. In the absence of appropriate tissue preparations, the characterization of novel ligands has generally been performed by using mammalian cell lines transfected with human or rodent D2 or D3 receptor subtypes and radioligands such as [125I]-iodosulpride or [3H]-spiperone that do not differentiate these sites (Chio et al., 1993; Millan et al., 1995; Sokoloffet al., 1992; Tang et al., 1994). On the basis of such studies, the aminotetralins (+)-AJ 76 and (+)-UH 232 were found to display a modest (about 2–5-fold) preference for D3 over D2 sites (Lévesque, 1996; Sokoloff et al., 1992; Van Vliet et al., 1996). Subsequently, several antagonists with improved selectivity at D3vs.D2 sites have been identified: the aminoindane U 99194 (Waters et al., 1993), the benzofurane (±)-S 11566 and its active (+)-isomer (+)-S 14297 (Gobert et al., 1995, 1996;Millan et al., 1994; 1995; Morris et al., 1997), the arylpiperazine GR 103,691 (Murray et al., 1995) and the benzamide derivative nafadotride (Sautel et al., 1996). Of these, (+)-S 14297 has been extensively employed in the functional evaluation of the potential significance of D3 receptorsin vivo. It has been shown that (+)-S 14297 inhibits the hypothermia induced by dopaminergic agonists such as (+)-7-OH-DPAT and quinpirole in rodents, which suggests an involvement of D3receptors in the control of CT (Millan et al., 1994; 1995;Rivet et al., 1996). At comparable doses, (+)-S 14297 neither modifies PRL secretion nor induces catalepsy in rats, two responses reflecting blockade of D2 receptors (Broccoet al., 1995; Millan et al., 1995; 1997). Interestingly, (+)-S 14297 does not modify the synthesis or release of DA in cerebral tissues, and it fails to modify the activity of ventral tegmental area-localized dopaminergic neurons (Gobert et al., 1995; Lejeune and Millan, 1995; Millan et al., 1995; Rivet et al., 1994; 1996). These observations suggest that D2 rather than D3 autoreceptors tonically inhibit the activity of central dopaminergic neurons. Nevertheless, (+)-S 14297 attenuates the inhibitory influence of (+)-7-OH-DPAT and (+)-PD 128,907 upon DA release and synthesis, which suggests that D3 (auto)receptors may contribute to the “phasic” inhibition of dopaminergic pathways (Gobert et al., 1995;Lejeune and Millan, 1995; Rivet et al., 1994).

Evidently, there now exist several antagonists and agonists of potential utility for the in vitro and in vivofunctional characterization of actions mediated by D3receptors. However, there has not yet been any comparative evaluation of the properties of these ligands. Thus, using the radioligands [3H]-(+)-S 14297 and [3H]-(+)-PD 128,907, both of which have recently been radiolabeled (Akunne et al., 1995; Newman-Tancredi et al., 1995), as well as the mixed D2/D3 antagonist [125I]-iodosulpride, the present study undertook a comparative evaluation of the binding profiles of (+)-S 14297, nafadotride, U 99194, GR 103,691, (+)-AJ 76, (+)-UH 232 and haloperidol at recombinant hD2 and hD3 receptors. In addition, we examined their in vivo actions in models of putative activity at D3 receptors (hypothermia) and D2 receptors (catalepsy, PRL secretion and DA synthesis). These analyses allowed for the classification of drugs in terms of 1) their rank order of potency at hD3 receptors and 2) their rank order of selectivity for hD3vs.hD2 receptors. In addition, a direct comparison of drug doses in putative models of D3 as compared with D2 receptor-mediated activity was possible.

Material and Methods

Binding at cloned, human D2 and D3receptors.

Binding studies were carried out at recombinant hD2 receptors (Receptor Biology, Beltsville, MA) and hD3 receptors (J.-C. Schwartz, INSERM, Paris, France) expressed in CHO cell lines as described previously (Millan et al., 1995). Briefly, affinities at hD2 and hD3 receptors were determined using [125I]-iodosulpride (0.1 and 0.2 nM for D2and D3, respectively), [3H]-(+)-S 14297 (7 nM for D3) and [3H]-(+)-PD 128,907 (2 nM for D3). Nonspecific binding was defined using 10 μM raclopride. Binding conditions for [125I]-iodosulpride and [3H]-(+)-S 14297 were as previously described (Newman-Tancredi et al., 1995; Sokoloff et al., 1992), and they were the same for [3H]-(+)-PD 128,907 except that incubations were carried out for 90 min.

Binding at other sites.

Binding conditions at other receptor sites were as described in Millan et al. (1995). For each receptor, the tissue, radioligand and ligands used to define nonspecific binding were as follows: hD4 receptors (4-repeat variant) expressed in CHO cells; [3H]-spiperone (0.2 nM); haloperidol 10 μM; rat striatal D2 receptors; [3H]-spiperone (0.1 nM), raclopride 10 μM; rat hippocampal 5-HT1A receptors and cloned, human serotonin (h5-HT1A) receptors expressed in CHO cells; [3H]-(±)-8-OH-DPAT (0.4 nM); 5-HT 10 μM; cloned, human muscarinic (hM1) receptors expressed in CHO cells; [3H]-N-methylscopolamine (0.5 nM); atropine 10 μM; rat frontal cortex alpha-1 adrenoceptors; [3H]-prazosin (0.2 nM); phentolamine 10 μM.

Influence on CT.

For evaluation of the influence of drugs alone on CT, basal CT was determined, drug or vehicle was administered, and CT was determined again 30 min later. This time corresponds to that at which (+)-PD 128,9078 and (+)-7-OH-DPAT exert their maximal influence on CT (Salmi et al., 1993; Dekeyne, A., unpublished observation). The difference between basal and postdrug values was calculated. For antagonist studies, the procedure was as follows. Basal CT was measured, drug or vehicle was administered and (+)-7-OH-DPAT, (+)-PD 128,907 or vehicle was administered 30 min later. A further 30 min later, CT was reevaluated and the difference from basal values calculated. The percent of drug inhibition of the actions of (+)-7-OH-DPAT and (+)-PD 128,907 was computed as 1-[(antagonist + agonist) − vehicle alone)/(vehicle + agonist) − vehicle alone)] × 100. Drug potency was expressed as ID50 95% CL.

Evaluation of catalepsy.

Catalepsy was determined in rats using a previously described procedure (Waldmeier and Delini-Stula, 1979). The animals were placed in a position whereby the left and right hind paws were crossed over the ipsilateral front paws; the time during which this position was maintained was determined up to a maximum of 30 sec. The mean value of three consecutive tests, separated by intervals of 1 min, was determined. Cataleptogenic potency was expressed in terms of AD50 (95% CL)—that is, the dose required for the induction of a half-maximal response (equivalent to 15 sec).

Evaluation of PRL secretion.

As described previously (Gobertet al., 1995), we measured PRL 30 min after drug administration in plasma by radioimmunoassay, using a highly specific (<0.5% cross-reactivity to all other hormones examined) antibody against rat PRL (Amersham, Buckingham, England). The detection limit was 70 pg/tube, and the intravariation and interassay variation were 5% and 15%, respectively. Because there is no theoretical limit to PRL levels in plasma, the MED was defined as the lowest dose significantly different (P < .05) from vehicle control values in Dunnett’s test after ANOVA.

Evaluation of DA turnover.

The method we used was described previously (Gobert et al., 1995). The effect of drugs alone was determined 30 min after their s.c. injection. The striatum, nucleus accumbens, olfactory tubercle and frontal cortex were examined (the inclusion of a portion of cingulate cortex in “frontal” cortex should be noted).

Tissues were homogenized in 500 μl of 0.1 M HClO4containing 0.5% Na2S2O5 and 0.5% EDTA Na2 and centrifuged at 15,000 × g for 15 min at 4°C. Supernatants were diluted in the mobile phase and injected into a HPLC column (Hypersil ODS 5 μm, C18, 150 × 4.6 mm (Thermo Quest, Les Ulis, France) maintained at 25°C). The mobile phase of the HPLC was KH2PO4, 100 mM; EDTA Na2, 0.1 mM; sodium octylsulphonate, 0.5 mM; methanol 5% adjusted to pH 3.15 with PO4H3. The flow rate was 1 ml/min. Electrochemical detection was performed using a Waters M460 detector with a working potential of 850 mV against an Ag/AgCl reference. Quantitative determinations were made by comparison with appropriate external standards. Levels of DA and DOPAC were expressed as a function of the tissue content of protein, with bovine serum albumin (Sigma Chemical Co., St. Louis, MO) as the standard. As an index of turnover, the ratio of DOPAC:DA was calculated. For each experiment, the mean levels of DA and DOPAC and the DOPAC:DA ratios were determined. They were expressed relative to values in animals treated with vehicle (defined as 100%). The influence of drugs was expressed as a percentage thereof. Drug potency was expressed as AD50 (95% CL)—that is, an increase in DOPAC:DA ratios to 150% relative to vehicle values.

Electrical activity of serotonergic neurons in the DRN.

As described in detail previously (Lejeune et al., 1994), rats were anesthetized with chloral hydrate (500 mg/kg s.c.). The femoral vein was cannulated and the rat placed in a stereotaxic apparatus. A tungsten electrode was lowered into the DRN, and the firing activity was measured by means of a Spike 2 analysis system obtained from Cambridge Electronic Design (Cambridge, U.K.). Drug effects were quantified over 60-sec bins at their time of maximal effect (1–2 min) after their injection i.v. Administered alone, GR 103,691 was injected in cumulative doses every 2 min. It was also injected at a single dose 2 min after administration of the 5-HT1A receptor agonist (±)-8-OH-DPAT (0.005 mg/kg i.v.). Firing rates were expressed as a percentage of basal, preinjection values (defined as 100%). The mean, basal firing rate was 1.1 Hz.

Data analysis and statistics.

All binding data were analysed with nonlinear regression (“Prism,” GraphPad, San Diego, CA).Ki values were calculated according to the Cheng-Prussof equation, Ki = IC50/(1 + L/Kd ), where IC50 is the concentration of compound that gives 50% inhibition of radioligand binding, L is the concentration of radioligand and Kd is the dissociation constant of the radioligand. In vivo dose-response curves were initially analyzed by ANOVA followed by Dunnett’s test, for which the level of significance was set at P < .05. As indicated above, MEDs, ID50 values, AD50 values or AD150 values were determined to estimate drug potencies. MOEs of drugs were also calculated.

Drugs and chemicals.

[125I]-Iodosulpride (2000 Ci/mmol) and [3H]-(+)-PD 128,907 (90–130 Ci/mmol) were purchased from Amersham, and [3H]-(+)-S 14297 (145 Ci/mmol) was radiolabeled by C.E.A (Gif-sur-Yvette, France). Forin vitro binding studies, drugs were dissolved in water or in dimethylsulfoxide. For in vivo studies, drugs were dissolved in sterile water, plus a few drops of lactic acid if necessary, and pH was adjusted to as close to neutrality (>5.0) as possible. Drugs were injected s.c., and doses are expressed in terms of the base. Drug sources, salts and structures were as follows: (+)-AJ 76 and (+)-UH 232 (Tocris Cookson, Southampton, England); (+)-7-OH-DPAT HCl (J. Besselièvre, CNRS, Paris, France); (+)-PD 128,907 HCl and (±)-8-OH-DPAT HBr (Research Biochemicals, Inc., Natick, MA) and haloperidol base (Sigma, Chesnes, France). (±)-S 11566 HCl, (+)-S 14297 dibenzoyltartrate, (−)-S 17777 dibenzoyltartrate, U 99194 HCl, GR 103,691 and nafadotride were synthesized by Servier chemists (J.-L. Peglion and G. Lavielle).

Results

In vitro ligand binding at hD3 and hD2 receptors.

In an initial series of experiments, we investigated the binding characteristics of [3H]-(+)-PD 128,907 to hD3 receptors. [3H]-(+)-PD 128,907 associated rapidly and monophasically with a t1/2 of 21 ± 3 min. Dissociation of [3H]-(+)-PD 128,907 from hD3 receptors was biphasic with a t1/2value for the first component of the isotherm of 58 ± 8 min (k−1 = 0.013 ± 0.002 min−1). The second component of the isotherm dissociated slowly, with 27% ± 1% of binding still remaining after 6 hr of incubation. An estimate of the Kd derived from the association and dissociation (rapid component) constants yielded a value of 0.6 nM. In saturation binding experiments, [3H]-(+)-PD 128,907 yielded a Kd value at hD3 receptors of 1.61 ± 0.31 nM. The Bmax value (6.06 ± 0.59 pmol/mg) was similar to that determined with [125I]-iodosulpride in the same membrane preparation (not shown). Antagonist competition binding isotherms at hD3receptors were derived for the preferential D3 receptor agonist [3H]-(+)-PD 128,907, the D3antagonist [3H]-(+)-S 14297 and the D2/D3 antagonist [125I]-iodosulpride (fig.1). Ki values at hD3 receptors were similar regardless of the radioligand used (table 1). The rank order of antagonist potency against [3H]-(+)-PD 128,907 binding at hD3 sites was GR 103,691 > nafadotride > haloperidol > (+)-UH 232 > (+)-S 14297 > (±)-S 11566 > (+)-AJ 76 > U 99194 > (−)-S 17777. The agonists (+)-7-OH-DPAT and (+)-PD 128,907 yielded biphasic isotherms at hD2 receptors (table 1, legend). The selectivity ratios (Ki , hD2/Ki , hD3) for the three radioligands are shown in table 1. (±)-S 11566, its isomer (+)-S 14297 and GR 103,691 exhibited the highest selectivity for hD3 receptors. Affinities at hD3 receptors correlated positively between radioligands with coefficients (r values) of +0.98 to +0.99. The affinity of the antagonists at other key receptor subtypes was determined.Ki values are shown for hD4, h5-HT1A and hM1 receptors and for ratalpha-1 adrenoceptors (table2). (+)-AJ 76 was only 8-fold more selective for hD3 than for hD4 receptors, and GR 103,691 was only 11-fold more selective for hD3 than for h5-HT1A receptors. (+)-S 14297 exhibited modest affinity at hM1 receptors, for which its affinity was 30-fold less than at hD3 receptors labeled by [3H]-PD 128,907 (Millan et al., 1995).

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Competition binding of dopaminergic antagonists at cloned, hD3 and hD2 receptors expressed in CHO cells. [3H]-(+)-PD 128,907, hD3 (panel A), [3H]-(+)-S 14297, hD3 (panel B) and [125I]-iodosulpride, hD3 (panel C). Competition binding experiments at hD2 receptors were carried out against [125I]-iodosulpride (panel D). Points shown are means of triplicate determinations from a single, representative experiment performed at least three times.

View this table:
  • View inline
  • View popup
Table 1

Affinities of dopaminergic antagonists at hD3, hD2 and rat D2 receptors determined by competition with different radioligands

View this table:
  • View inline
  • View popup
Table 2

Binding affinities (Ki values) of dopaminergic ligands at key receptors

Electrical activity of DRN-localized serotonergic neurons.

Administered at a dose of 5 μg/kg i.v., (±)-8-OH-DPAT completely abolished the firing rate of DRN serotonergic neurons (−100.0 ± 0.0% relative to vehicle values, defined as 0%). Further, thealpha-1 adrenoceptor antagonist prazosin (150 μg/kg i.v.) reduced firing levels to −77.9 ± 6.4% of vehicle values. Both effects were significant in Student’s two-tailed t test (P < .05). By contrast, administered in incremental doses up to 500 μg/kg i.v., GR 103,691 failed (±0.0 ± 5.5%) to modify the firing rate of these neurons. Similarly, at a dose of 250 μg/kg i.v., GR 103,691 did not modify the influence of 8-OH-DPAT on DRN firing (−100.0 ± 0.0%).

Blockade of (+)-PD 128,907- and (+)-7-OH-DPAT-induced hypothermia.

Both (+)-PD 128,907 and (+)-7-OH-DPAT dose-dependently elicited hypothermia (fig.2). Their actions were prevented by (±)-S 11566, as well as by its active eutomer (+)-S 14297, whereas the inactive distomer (−)-S 17777 was ineffective (table3; fig. 3). (+)-AJ 76, (+)-UH 232, nafadotride and U 99194 also antagonized (+)-PD 128,907- and (+)-7-OH-DPAT-induced hypothermia, whereas GR 103,691 was inactive (table 3; fig. 3). Haloperidol was active at low doses. Antagonist potencies in blocking PD 128,907- and (+)-7-OH-DPAT-induced hypothermia were highly correlated (r = 0.97, P < .01).

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2

Dose-dependent induction of hypothermia by the preferential agonists at hD3 receptors, (+)-PD 128,907 and (+)-7-OH-DPAT. The data represent the difference between basal and post-treatment values and are means ± S.E.M. (n≥ 5 per value). ANOVA results: (+)-PD 128,907, F(6,31) = 55.8, P < .01 and (+)-7-OH-DPAT, F(4,38) = 51.1, P < .01. * Significantly different from vehicle values in Dunnett’s test after ANOVA; P < .05.

View this table:
  • View inline
  • View popup
Table 3

Inhibition of (+)-PD 128,907- and (+)-7-OH-DPAT-induced hypothermia by dopaminergic antagonists

Figure 3
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3

Dose-dependent blockade of (+)-PD 128,907-induced hypothermia by dopaminergic antagonists. Antagonists were given 30 min before (+)-PD 128,907 (0.63 mg/kg s.c.) (closed symbols) or vehicle (open symbols). Data are means ± S.E.M. (n ≥ 4 per value). ANOVA results follow. Panel A: (±)-S 11566/vehicle,F(3,25) = 4.4, P < .05; (±)-S 11506/(+)-PD 128,907,F(3,15) = 24.5, P < .001; (+)-S 14297/vehicle,F(3,33) = 8.5, P < .001; (+)-S 14297/(+)-PD 128,907,F(3,15) = 12.4, P < .001; (−)-S 17777/vehicle,F(2,12) = 3.1, P > .05; (−)-S 17777/(+)-PD 128,907,F(3,16) = 3.7, P < .05. Panel B: (+)-UH 232/vehicle,F(3,10) = 0.3, P > .05; (+)-UH 232/(+)-PD 128,907,F(3,17) = 15.7, P < .01; (+)-AJ 76/vehicle,F(3,30) = 4.0, P < .05; (+)-AJ 76/(+)-PD 128,907,F(3,14) = 12.5, P < .01; nafadotride/vehicle,F(3,13) = 1.6, P > .05. Panel C: nafadotride/(+)-PD 128,907, F(4,18) = 19.4, P < .01; U 99,194/vehicle,F(3,11) = 0.2, P > .05; U 99,194/(+)-PD 128,907,F(4,26) = 11.1, P < .01 and GR 103,691/(+)-PD 128,907,F(3,13) = 0.8, P > .05. * Significantly different from vehicle/(+)-PD 128,907 values in Dunnett’s test after ANOVA: P < .05.

Induction of catalepsy, PRL secretion and DA synthesis by dopaminergic antagonists.

Haloperidol potently elicited catalepsy, increased plasma PRL levels and elevated DA synthesis (tables4 and 5; fig. 4). (+)-AJ 76, (+)-UH 232 and nafadotride likewise induced both PRL secretion and DA synthesis (tables 4 and 5; fig. 4). U 99194 failed to elicit catalepsy and increased PRL release and DA turnover only at very high doses (40.0 mg/kg). (+)-S 14297 and GR 103,691 were devoid of activity in each of these models (tables 4 and 5; fig. 4).

View this table:
  • View inline
  • View popup
Table 4

Induction of catalepsy and PRL secretion by dopaminergic antagonists

View this table:
  • View inline
  • View popup
Table 5

Influence of dopaminergic antagonists on DA turnover

Figure 4
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4

Dose-dependent induction by dopaminergic antagonists of catalepsy (panel A), PRL secretion (panel B) and striatal DA synthesis (panel C). Data are means ± S.E.M. (n≥ 4 per value). ANOVA results follow. Catalepsy: (+)-AJ 76,F(4,26) = 4.8, P < .05; GR 103,691, F(3,18) = 0.6, P > .05; haloperidol, F(4,43) = 58.3, P < .05; nafadotride, F(3,26) = 11.8, P < .05; (+)-UH 232,F(3,19) = 11.7, P < .05; U 99194, F(2,8) = 0.8, P > .05 and (+)-S 14297, F(2,12) = 1.5, P > .05. Prolactin secretion: (+)-AJ 76, F(4,32) = 9.7, P < .05; GR 103,691, F(3,30) = 0.8, P > .05; haloperidol, F(5,47) = 18.7, P < .05; nafadotride,F(5,36) = 24.3, P < .05; (+)-UH 232,F(3,13) = 5.8, P < .05; U 99194, F(4,15) = 17.7, P < .05 and (+)-S 14297, F(4,28) = 0.5, P > .05. Striatal DA synthesis: GR 103,691, F(1,6) = 3.5, P > .05; nafadotride, F(4,19) = 90.5, P < .01; (+)-UH 232, F(3,12) = 34.5, P < .01; U 99194,F(3,17) = 108.2, P < .01 and S 14297,F(3,31) = 0.7, P > .05. (+)-AJ 76 and haloperidol data are from Gobert et al., (1995). * Significantly different from vehicle values in Dunnett’s test after ANOVA; * P < .05.

Discussion

Competition binding studies.

All antagonists displayed similar affinities at hD3 receptors irrespective of the radioligand used, though slightly higher affinities were generally observed with [3H]-(+)-PD 128,907. This observation may reflect the capacity of agonist radioligands to stabilize hD3 receptors in a high-affinity conformation, an interpretation consistent with its slow dissociation (“Results”) and implied by a ternary complex model of receptor coupling (Kenakin, 1996). In any case, a similar order of hD2/hD3selectivity was observed regardless of the D3 radioligand. With subnanomolar affinities, GR 103,691 and nafadotride were potent ligands at hD3 receptors (Murray et al., 1995;Sautel et al., 1996). The hD2/hD3selectivity ratio of nafadotride was, however, only modest, whereas GR 103,691 showed 60-fold selectivity. Because of a higher affinity at D2 sites in our hands, this value is about 2-fold less than that previously reported (table 1; Murray et al., 1995) but is still pronounced. (±)-S 11566 and its active eutomer (+)-S 14297 also exhibited marked selectivity ratios at D3vs. D2 sites, whereas a modest hD2/hD3 selectivity ratio was obtained for the less active distomer (−)-S 17777, as well as for U 99194 (Millanet al., 1994; 1995; Waters et al., 1993). Overall, the lowest D2/D3 ratios were observed for (+)-AJ 76 and (+)-UH 232 and the highest for (+)-S 14297 and GR 103,691 (table 1). However, GR 103,691 displayed high affinity at 5-HT1A receptors and alpha-1 adrenoceptors (table 2), in accordance with the findings of Murray et al.(1994). (+)-S 14297 also showed modest (about 30 fold-lower) activity at muscarinic hM1 receptors (Millan et al., 1995). Nevertheless, among the ligands tested, (+)-S 14297 presents a reasonable combination of marked hD3 affinity, pronounced hD3/hD2 selectivity and modest interactions at other receptor sites. Indeed, (+)-S 14297 shows ≥100-fold lower affinity at hD1 and hD5 receptors, multiple serotonergic and adrenergic receptors and all other sites (>50) as yet examined, with the exception of ς1 sites, for which it shows modest affinity (196 nM) (Millan et al., 1995).

Induction and blockade of hypothermia.

In a recent study, the comparative importance of D2 and D3 sites in mediating hypothermia was addressed in detail (Millan et al., 1994; 1995; Rivet et al., 1996). In a result consistent with a putative role of D3 receptors, (+)-PD 128,907 elicited hypothermia herein (fig. 2). Notwithstanding its superior affinity at D3 (and D2) receptors as compared with (+)-7-OH-DPAT (table 1; Akunne et al., 1995;Bristow et al., 1996), (+)-PD 128,907 was lesspotent in decreasing CT. We have also noted an inferior potency of (+)-PD 128,907 relative to (+)-7-OH-DPAT in a diversity of in vivo models in which pre- and/or postsynaptic D3and/or D2 receptors are implicated, including a reduction of locomotion, inhibition of the firing rate of ventral tegmental area-localized dopaminergic neurons and suppression of PRL secretion (Brocco et al., 1995; Gobert et al., 1995; Lejeune, F., unpublished observation). Collectively, these observations suggest that (+)-PD 128,907 is a less potent ligand than (+)-7-OH-DPAT in vivo, which probably reflects differential absorption, metabolism or access to the CNS.

(±)-S11566 and (+)-S 14297, but not (−)-S 17777, stereospecifically block the induction of hypothermia by (+)-7-OH-DPAT (table 3; fig. 3) (Millan et al., 1994; 1995). These data are extended herein to antagonism of the hypothermic actions of (+)-PD 128,907. The inability of GR 103,691 to block hypothermia, even at high doses, may reflect its poor in vivo bioavailability (see below). By contrast, the preferential D3 antagonists U 99194 and nafadotride both antagonized hypothermia elicited by (+)-7-OH-DPAT and (+)-PD 128,907 (table 3; fig. 3). The modestly preferential D3 antagonists (+)-UH 232 and (+)-AJ 76 likewise blocked the actions of (+)-7-OH-DPAT and (+)-PD 128,907, and, like all other antagonists, they did not modify basal CT. The lack of influence of (+)-UH 232 on basal CT is of note inasmuch as a recent study of transfected NG 10815 cells, employing stimulation of mitogenesis as a measure of coupling efficacy, suggested that (+)-UH 232 behaves as a weak partial agonist at D3 receptors (Griffon et al., 1995). However, it is difficult to compare efficacies at heterologously expressed receptors in cell lines to those at native receptors in situ. Further, the NG 10815/hD3receptor expression system possesses a high receptor density and is probably of greater sensitivity than the population of postsynaptic D3 receptors thought to mediate hypothermia (Lajinesset al., 1993; Millan et al., 1995; Sautelet al., 1995). Although the present data are consistent with a role of D3 receptors in the induction of hypothermia, a role of D2 sites should not be excluded, and the availability of more selective D2 and D3receptor antagonists, as well as studies in transgenic mice, will be necessary for a further evaluation of the respective roles of D3 and D2 receptors in controlling CT.

PRL secretion, DA synthesis and catalepsy: blockade of tonically active D2 receptors.

Tuberoinfundibular dopaminergic pathways exert a tonic, inhibitory control on the secretion of PRL (Ben-Jonathan et al., 1989; McDonald et al., 1984). Although multiple dopaminergic receptor types may indirectly modulate PRL secretion via these tuberoinfundibular neurons (Berry and Gudelsky, 1990), dopaminergic ligands modulate PRL secretion primarily via actions at dopaminergic receptors on lactotrophs in the adenohypophysis (McChesney et al., 1991). Neuroanatomical studies have indicated that these are of the D2 type (Levant et al., 1993; Lévesque, 1996). Pharmacological support for a predominant role of D2receptors has also been obtained. Thus the relative potencies of dopaminergic agonists and antagonists in decreasing and increasing PRL secretion, respectively, correlate with their affinity at D2 (but not D3) sites (Millan et al., 1995; Rivet et al., 1996). Indeed, compared with haloperidol, (+)-S 14297 modified PRL secretion very little (fig. 4). Further, U 99194, in line with its low D2 affinity, exerted only a weak influence on PRL levels. A previous study has also reported that (+)-AJ 76 weakly modifies PRL secretion in vivo(Eriksson et al., 1986). Although GR 103,691 was also inactive, this observation must be interpreted in the light of the following comments about its poor activity in vivo. Indeed, the affinity of GR 103,691 at hD2 receptors is virtually identical to that of (+)-UH 232, which potently elicited PRL secretion.

There is anatomical (Bouthenet et al., 1991; Diazet al., 1995; Gehlert et al., 1992; Herroelenet al., 1994; Larson et al., 1995; Lévesqueet al., 1992; Richtand et al., 1995;Meador-Woodruff et al., 1996), electrophysiological (Devoto et al., 1995; Lejeune and Millan, 1995), behavioral (Sanger et al., 1996) and biochemical (Gainetdinov et al., 1995; 1996; Gobert et al., 1995; 1996; O’Hara et al., 1996; Rivet et al., 1994; 1996; Tang et al., 1994) evidence that D3 receptors contribute to the phasic, inhibitory control of ascending dopaminergic pathways. However, D3 (auto)receptors do not appear to inhibittonically the activity of dopaminergic neurons (Koeltzow et al., 1998; Millan et al., 1995). Rather, this role is fulfilled by colocalized D2autoreceptors (Bowery et al., 1994; 1996; Meador-Woodruffet al., 1996; Mercuri et al., 1997; Millanet al., 1995; Momiyama et al., 1993; Pierceyet al., 1996; Seabrook et al., 1995). Correspondingly, the facilitation of DA synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways reflects inactivation of D2 receptors, and this parameter was not significantly affected by (+)-S 14297. Thus the increase in DOPAC:DA levels provoked by (+)-UH 232 and (+)-AJ 76 supports previous studies performed with other procedures in suggesting that they accelerate DA turnover by blockade of D2 autoreceptors (Waters et al., 1994a). Furthermore, the induction of DA synthesis by nafadotride extends a previous study of Sautel et al. (1995)in which, over a similar dose range, nafadotride increased levels of DA metabolites in the striatum. The modest influence of U 99194 on DA turnover is also consistent with its weak affinity at these sites (Waters et al., 1993).

An enhancement in striatal DA turnover is generally correlated with the induction of catalepsy, a behavior attributed to blockade of postsynaptic dopaminergic receptors in the striatum and predictive of an extrapyramidal syndrome in the human (Casey, 1993). Support for an opposite control of motor behavior by D3vs.D2 receptors, and for a role of D2 receptors in mediating catalepsy, may be derived from several lines of study. First, knockout mice that lack D2 receptors display a catalepsy-like state, whereas mice with a null mutation for D3 receptors are hyperactive (Accili et al., 1996; Baik et al., 1995). Second, the preferential activation of postsynaptic D2 and of D3receptors enhances and depresses locomotor behavior, respectively (Bristow et al., 1996; Depoortere et al., 1996;Khroyan et al., 1995; Kling-Petersen et al., 1995; Sanger et al., 1996). Third, blockade of postsynaptic D2 and D3 receptors respectively suppresses and enhances (though more variably) locomotor activity (Millan et al., 1997; Sautel et al., 1996; Svensson et al., 1994; Waters et al., 1993; 1994b). Fourth, D2 and D3 receptors exert an opposite control of gene expression of neurotensin in the nucleus accumbens, a neuropeptide that modulates locomotor behavior (Diaz et al., 1994). Fifth, the potency of dopaminergic antagonists in eliciting catalepsy correlates closely with affinity at D2 receptors (Millan et al., 1997). Sixth, (+)-S 14297 inhibits the induction of catalepsy by haloperidol (Brocco et al., 1995;Millan et al., 1997). In analogy to the lack of cataleptogenic potential of (+)-S 14297, U 99194 failed to elicit catalepsy herein (fig. 4) and increases locomotor activity by an action at postsynaptic D3 receptors (Waters et al., 1994b). Similarly, low doses of nafadotride increase motor behavior (Sautel et al., 1995), whereas higher doses elicit catalepsy (Sautel et al., 1995) (fig. 4). The cataleptic actions of nafadotride, (+)-UH 232 and (+)-AJ 76 at high doses evidently reflect blockade of D2 receptors. In analogy to the other models of activity at D2 receptors, GR 103,691 was inactive.

Mechanisms underlying induction of catalepsy, PRL secretion and DA turnover.

The patterns of data obtained in the models of PRL secretion, induction of cerebral DA turnover and catalepsy were broadly similar. In contrast to the potent actions of haloperidol, (+)-S 14297 was inactive and U 99194 displayed modest activity. Nafadotride, (+)-UH 232 and (+)-AJ 76, which manifest only a mild preference for D3 receptors, displayed an intermediate pattern of behavior. Thus these in vivo findings correspond to the relative preference of these antagonists for D3vs. D2 sites in vitro. Interestingly, differences among the antagonists were apparent not only as concerns their relative potencies but also as regards their maximal effects. Thus haloperidol consistently produced the most marked actions, (+)-S 14297 was inactive, U 99194 was weakly active and the other antagonists provoked intermediate responses (tables 4 and 5; fig. 4). The question arises why maximal effects should differ. If antagonist actions simply reflected interruption of the activity of spontaneously released DA at D2 receptors, they should, in theory, all elicit the same maximal effect. There are several possible explanations. First, the non-D2 (or D3) receptor interactions of drugs may modify their respective maximal effects. Second, the dose ranges of drugs employed may have been insufficient to occupy D2receptors substantially. This may be the case for (+)-S 14297, but dose-response curves for other drugs were pursued up to doses at which D2 antagonist properties are clearly expressed (Broccoet al., 1995; Brocco, M., unpublished observation). Third, a functional interplay between postsynaptic D2 and D1 sites is well established (Creese and Fraser, 1987), and D2 and D3 receptors colocalized on individual neurons may mutually oppose each other’s activities (Surmeier et al., 1992; Le Moine and Bloch, 1996). Indeed, as mentioned above, the enhancement of motor behavior by D3 receptor blockade counters the motor-suppressive effects of D2 receptor antagonism (Millan et al., 1995; 1997). Thus, for the ligands tested herein, a progressive reduction in cataleptogenic potential paralleled a progressive reinforcement of D3vs. D2 antagonist preference. A fourth possibility is that haloperidol behaves as an inverse agonist at D2 receptors (Hall and Strange, 1997; Nilsson et al., 1996). A differential degree of inverse agonist activity at D2 sites could explain the contrasting maximal effects of antagonists on PRL secretion, etc. (fig. 4). However, the concept of inverse agonist actions cannot easily explain the occurrence of catalepsy in D2 knockout mice (Baik et al., 1995). Further, like haloperidol, clozapine is an inverse agonist at D2 receptors, but it does not evoke catalepsy (Hall and Strange, 1997). Irrespective of the reasons underlying the difference in maximal effects, the present data suggest that antagonists possessing a marked preference for D3 versus D2receptors may have a low extrapyramidal syndrome potential.

The inactivity of GR 103,691.

Pharmacokinetic factors also contribute to differential drug effects, and GR 103,691 was inactive, even at high doses relative to its in vitro affinities, in each of the in vivo paradigms employed herein. It was recently shown that, in contrast to haloperidol, GR 103,691 does not influence cerebral c-fos expression (Hurley et al., 1996). Indeed, the only in vivo effect documented to date for GR 103,691 is its ability to block the locomotion elicited by infusion of muscimol into the ventral tegmental area (Murray et al., 1995). In this model, GR 103,691 (0.3 mg/kg s.c.) was 6-fold less potent than haloperidol (0.05 mg/kg s.c.) despite its 5-fold higher affinity at D3 receptors, an observation in line with the present data indicating a lower bioavailability than anticipated. However, its low affinity at D3 receptors (Ki = 200 nM) notwithstanding, clozapine (0.005 mg/kg s.c.) was more potent than GR 103,691 in blocking the actions of muscimol. This observation suggests that activity in this model may reflect the involvement of receptors other than, or in addition to, D3 sites. Thus, to date, there are no unambiguous data for functional actions of GR 103,691 at D3 (or D2) sites in vivo. We have, moreover, found that high doses of GR 103,691 (10 mg/kg s.c.) are inactive in several other behavioral models of D2 receptor-mediated activity in rats, including inhibition of amphetamine-induced locomotion and reduction of conditioned avoidance responses (Brocco, M., unpublished observation) models, whereas haloperidol is active, with ID50 values of 0.04 and 0.05 mg/kg s.c., respectively. In addition, haloperidol abolishes inhibition of the firing of dopaminergic neurons in the ventrotegmental area by (+)-PD 128,905 with an ID50 of 0.003 mg/kg i.v. In contrast, even at an 80-fold higher dose of 0.25 mg/kg i.v., GR 103,691 only partially (about 40%) inhibits the action of (+)-PD 128,907 (Lejeune, F., unpublished observation). Herein, we also examined this issue by exploiting the marked affinity of GR 103,691 for 5-HT1A receptors and alpha-1 adrenoceptors. Agonists at 5-HT1A sites and antagonists atalpha-1 adrenoceptors both inhibit serotonergic neurons in the DRN (Hjorth and Sharp, 1990; Lejeune et al., 1994). However, GR 103,691, at doses up to 0.5 mg/kg i.v., neither modified basal firing rates of serotonergic neurons nor attenuated the inhibitory influence on these of the 5-HT1A agonist (±)-8-OH-DPAT (see “Results”). These observations suggest that a lack of in vivo activity is a general property of GR 103,691 irrespective of the receptor type concerned. This electrophysiological study was performed by the i.v. route in order to minimize problems of metabolism. Further, GR 103,691 does not modify PRL secretion even though the relevant D2 receptors are localized outside the blood-brain barrier. Thus it is not clear whether rapid metabolism, poor CNS penetration and/or other factors underlie the low activity of GR 103,691 in vivo.

General discussion.

Of the ligands examined, (+)-S 14297 and GR 103,691 appear the most appropriate ligands for the characterization and differentiation of activity at D3 as compared with D2 receptors in vitro. In this regard, GR 103,691 possesses an advantage in terms of its higher affinity and overall selectivity for D3vs. D2sites. However, GR 103,691 displays the disadvantage of marked affinity at both 5-HT1A receptors and alpha-1 adrenoceptors. Although these properties may not interfere with its use in transfected cell lines, they compromise its utility in functional studies of more complex systems. Furthermore, GR 103,691 appears to possess little bioavailability in vivo. In this respect, although its modest affinity at hM1 and ς1receptors must be mentioned (Millan et al., 1995), (+)-S 14297 appears to be a more suitable ligand for in vivostudies. In fact, few ligands have been reported that possess a marked D3vs. D2 preference comparable to that of (+)-S 14297 and GR 103,691 in vitro. Moreover,in vivo data are generally not available. Nevertheless, the recently described, 2-substituted 2-aminotetralin GR 218,231 [2-(R,S)-(dipropylamino)-6-(4-methoxyphenylsulfonylmethyl)-1,2,3,4-tetrahydronaphtalene] possesses >100-fold selectivity for D3vs.D2 sites, and its functional actions in vivowill be of interest to explore (Murray et al., 1996). Moreover, a modestly preferential (10–20-fold) antagonist, L 741,626, at D2 receptors has been documented (Bowery et al., 1996). As concerns the D2 receptor “family” in general, several potent and selective D4 receptor antagonists have now become available, including S 18126 ({2-[4-(2,3-dihydro benzo [1,4]dioxin-6-yl) piperazin-1-yl methyl] indan-2-yl}) and L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2,3b]pyridine). Notably, both S 18126 and L 745,870 were inactive in the functional models employed herein, which indicates a lack of involvement of D4 receptors (Boyfield et al., 1996; Bristowet al., 1997; Kulagowski et al., 1996; Millanet al., 1996 and in press).

Conclusion.

In conclusion, the present data underpin the hypothesis that the selective blockade of D3 receptors does not provoke extrapyramidal side effects and fails to perturb dopaminergic transmission. On the other hand, whether an antagonist action at D3 receptors contributes to the therapeutic efficacy of antipsychotic drugs remains to be determined (Levant, 1997;Sokoloff and Schwartz, 1995). More generally, the potential significance of D3 receptors in depression, drug abuse and other psychiatric disorders requires further evaluation (Acri et al., 1995; Caine and Koob, 1993; Roberts and Ranaldi, 1995;Sokoloff and Schwartz, 1995; Spealman, 1996; Strange, 1993; Wallaceet al., 1996; Willner, 1983). To develop an improved understanding of the physiological and therapeutic significance of D3 (and D2) receptors, we need additional, chemically diverse, potent and selective D3 and D2 receptor antagonists.

Acknowledgments

We thank V. Pasteau, S. Aubry, C. Chaput, L. Verrièle, H. Gressier and S. Girardon for their excellent technical assistance.

Footnotes

  • Send reprint requests to: Dr. Mark J. Millan, Institut de Recherches Servier, Centre de Recherches de Croissy, Psychopharmacology Department, 125, Chemin de Ronde, 78290—Croissy-sur-Seine (Paris), France.

  • Abbreviations:
    AD
    active dose
    (+)-AJ 76
    {(+)-(cis-(+)-5-methoxy-1-methyl-2-(n-propylamino)tetralin}
    ANOVA
    analysis of variance
    CHO
    Chinese hamster ovary
    CT
    core temperature
    DA
    dopamine
    DOPAC
    dihydroxyphenylacetic acid
    DRN
    dorsal raphe nucleus
    ID
    inhibitory dose
    GR 103
    691, {4′-acetyl-N-{4-[(2-methoxy-phenyl)-piperazin-1-yl]-butyl}-biphenyl-4-carboxamide
    5-HT
    serotonin
    MED
    minimal effective dose
    MOE
    maximal observed effect
    (+)-7-OH-DPAT
    {(+)-7-hydroxy-2-(di-n-propylamino)-tetralin)
    (±)-8-OH-DPAT
    {(±)-8-hydroxy-2-(di-n-propylamino)-tetralin)}
    (+)-PD 128
    907, {(+)-(4aR,10bR)-3,4,4a,10b-tetrahydro-4-propyl-2H,5H-[1]-benzopyrano-[4,3-b]-1,4-oxazin-9-ol}
    PRL
    prolactin
    (+)-UH 232
    {cis-(+)-1S,2R-5-methoxy-1-methyl-2-(di-n-propylamino)tetralin}
    (±)-S 11566
    {(±)-[7-(N,N-dipropylamino)-5,6,7,8-tetrahydro-naphtho-(2,3b)-dihydro,2,3-furane]}
    (+)-S 14297
    {(+)-[7-(N,N-dipropylamino)-5,6,7,8-tetrahydro-naphtho-(2,3b)-dihydro,2,3-furane]}
    (−)-S 17777
    {(−)-[7-(N,N-dipropylamino)-5,6,7,8-tetrahydro-naphtho-(2,3b)-dihydro,2,3-furane]}
    U 99194
    {5,6-dimethoxy-indan-2-yl) dipropylamine}
    • Received September 8, 1997.
    • Accepted May 19, 1998.
  • The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    1. Accili D,
    2. Fishburn CS,
    3. Drago J,
    4. Steiner H,
    5. Lachowicz JE,
    6. Park B-H,
    7. Gauda EB,
    8. Lee EJ,
    9. Cool MH,
    10. Sibley DR,
    11. Gerfen CR,
    12. Westphal H,
    13. Fuchs S
    (1996) A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci 93:1945–1949.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Acri JB,
    2. Carter SR,
    3. Alling K,
    4. Geter-Douglass B,
    5. Dijkstra D,
    6. Wikström H,
    7. Katz JL,
    8. Witkin JM
    (1995) Assessment of cocaine-like discriminative stimulus effects of dopamine D3 receptor ligands. Eur J Pharmacol 281:R7–R9.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Akunne HC,
    2. Towers P,
    3. Ellis GJ,
    4. Dijkstra D,
    5. Wikström H,
    6. Heffner TG,
    7. Wise LD,
    8. Pugsley TA
    (1995) Characterization of binding of [3H]-PD 128907, a selective dopamine D3 receptor agonist ligand, to CHO-K1 cells. Life Sci 15:1401–1410.
    OpenUrlCrossRef
  4. ↵
    1. Baik H,
    2. Picetti R,
    3. Salardi A,
    4. Thiriet G,
    5. Dierich A,
    6. Depaulis A,
    7. Le Meur M,
    8. Borrelli E
    (1995) Parkisonian-like locomotor impairment in mice lacking dopamine D2 receptors. Lett Nature (Lond) 377:424–428.
  5. ↵
    1. Ben-Jonathan N,
    2. Arbogast LA,
    3. Hyde JF
    (1989) Neuroendocrine regulation of prolactin release. Prog Neurobiol 33:399–447.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Berry SA,
    2. Gudelsky GA
    (1990) Effect of dopamine D2 agonists on tuberoinfundibular dopamine neurons. J Pharmacol Exp Ther 254:677–682.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Bouthenet M-L,
    2. Souil E,
    3. Martres M-P,
    4. Sokoloff P,
    5. Giros B,
    6. Schwartz JC
    (1991) Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: Comparison with dopamine D2 receptor mRNA. Brain Res 564:203–219.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Bowery B,
    2. Rothwell LA,
    3. Seabrook GR
    (1994) Comparison between the pharmacology of dopamine receptors mediating the inhibition of cell firing in rat brain slices through the substantia nigra pars compacta and ventral tegmental area. Br J Pharmacol 112:873–880.
    OpenUrlPubMed
  9. ↵
    1. Bowery BJ,
    2. Razzaque Z,
    3. Emms F,
    4. Patel S,
    5. Freedman S,
    6. Bristow L,
    7. Kulagowski J,
    8. Seabrook GR
    (1996) Antagonism of the effects of (+)-PD 128907 on midbrain dopamine neurones in rat brain slices by a selective D2 receptor antagonist L-741,626. Br J Pharmacol 119:1491–1497.
    OpenUrlPubMed
  10. ↵
    1. Boyfield I,
    2. Brown TH,
    3. Coldwell MC,
    4. Cooper DG,
    5. Hadley MS,
    6. Hagan JJ,
    7. Healy MA,
    8. Johns A,
    9. King RJ,
    10. Middlemiss DN,
    11. Nash DJ,
    12. Riley GJ,
    13. Scott EE,
    14. Smith SA,
    15. Stemp G
    (1996) Design and synthesis of 2-naphthoate esters as selective dopamine D4 antagonists. J Med Chem 39:1946–1948.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Bristow LJ,
    2. Cook GP,
    3. Gay JC,
    4. Kulagowski JJ,
    5. Landon L,
    6. Murray F,
    7. Saywell KL,
    8. Young L,
    9. Hutson PH
    (1996) The behavioural and neurochemical profile of the putative dopamine D3 receptor agonist, (+)-PD 128,907, in the rat. Neuropharmacology 35:285–294.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Bristow LJ,
    2. Kramer MS,
    3. Kulagowski JJ,
    4. Patel S,
    5. Ragan CI,
    6. Seabrook GR
    (1997) Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist. Trends Pharmacol Sci 18:186–188.
    OpenUrlPubMed
  13. ↵
    1. Brocco M,
    2. Gressier H,
    3. Veiga S,
    4. Audinot V,
    5. Maurel-Remy S,
    6. Millan MJ
    (1995) Dopamine D3 receptor blockade does not inhibit motor behaviour and reduces haloperidol-induced catalepsy (Abstract). Am Soc Neurosci 21:618.
    OpenUrl
  14. ↵
    1. Caine SB,
    2. Koob GF
    (1993) Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science (Wash DC) 260:1814–1816.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Carta A,
    2. Rius R,
    3. Fuchs S,
    4. Accili D,
    5. Gerfen CR
    (1996) Characterization of D3 dopamine receptor function in knockout mice (Abstract). Am Soc Neurosci 22:1088.
    OpenUrl
  16. ↵
    1. Casey DE
    (1993) Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in non-human primates. Psychopharmacology 112:S55–S59.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Chio CL,
    2. Lajiness ME,
    3. Huff RM
    (1993) Activation of heterologously expressed D3 dopamine receptors: Comparison with D2 dopamine receptors. Mol Pharmacol 45:51–61.
    OpenUrlAbstract
  18. ↵
    1. Creese I,
    2. Fraser CM
    (1987) Receptor Biochemistry and Methodology (Alan R. Liss Inc. New York), 8: Dopamine Receptors.
  19. ↵
    1. Depoortere R,
    2. Perrault G,
    3. Sanger DJ
    (1996) Behavioural effects in the rat of the putative dopamine D3 receptor agonist 7-OH-DPAT: Comparison with quinpirole and apomorphine. Psychopharmacology 124:231–240.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Devoto P,
    2. Collu M,
    3. Muntoni L,
    4. Pistis M,
    5. Serra G,
    6. Gessa GL,
    7. Diana M
    (1995) Biochemical and electrophysiological effects of 7-OH-DPAT on the mesolimbic dopaminergic systems. Synapse 20:153–155.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Diaz J,
    2. Lévesque D,
    3. Griffon N,
    4. Lammers CH,
    5. Martres M-P,
    6. Sokoloff P,
    7. Schwartz J-C
    (1994) Opposing role for dopamine D2 and D3 receptors on neurotensin mRNA expression in nucleus accumbens. Eur J Neurosci 6:1384–1387.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Diaz J,
    2. Lévesque D,
    3. Lammers CH,
    4. Griffon N,
    5. Martres M-P,
    6. Schwartz J-C,
    7. Sokoloff P
    (1995) Phenotypical characterization of neurons expressing the dopamine D3 receptor in the rat brain. Neuroscience 65:731–745.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Eriksson E,
    2. Carlsson M,
    3. Clark D,
    4. Nilsson C,
    5. Svensson K
    (1986) Compounds with selectivity for dopamine autoreceptors: Effects of prolactin secretion in male and female rats. Clin Neuropharmacol 9:226–228.
  24. ↵
    1. Gainetdinov RR,
    2. Sotnikova TD,
    3. Grekhova TV,
    4. Rayevsky KS
    (1995) Estimation of the interstitial free concentration of the putative dopamine D3 receptor selective agonist 7-OH-DPAT in the dorsal striatum of freely moving rats. Neurosci Lett 193:65–67.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Gainetdinov RR,
    2. Sotnikova TD,
    3. Grekhova TV,
    4. Rayevsky KS
    (1996) In vivo evidence for a preferential role of dopamine D3 receptor in the presynaptic regulation of dopamine release but not synthesis. Eur J Pharmacol 308:261–269.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Gehlert DR,
    2. Gackenheimer SL,
    3. Seeman P,
    4. Schaus J
    (1992) Autoradiographic localization of [3H]quinpirole binding to dopamine D2 and D3 receptors in rat brain. Eur J Pharmacol 211:189–192.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Gobert A,
    2. Lejeune F,
    3. Rivet J-M,
    4. Cistarelli L,
    5. Millan MJ
    (1996) Dopamine D3 (auto) receptor inhibits dopamine release in the frontal cortex of freely-moving rats in vivo. J Neurochem 66:2209–2212.
    OpenUrlPubMed
  28. ↵
    1. Gobert A,
    2. Rivet J-M,
    3. Audinot V,
    4. Cistarelli L,
    5. Spedding M,
    6. Vian J,
    7. Peglion J-L,
    8. Millan MJ
    (1995) Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297. II. Both D2 and “silent” D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J Pharmacol Exp Ther 275:899–913.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Griffon N,
    2. Pilon C,
    3. Schwartz J-C,
    4. Sokoloff P
    (1995) The preferential dopamine D3 receptor ligand, (+)-UH 232, is a partial agonist. Eur J Pharmacol 282:R3–R4.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Hall DA,
    2. Strange PG
    (1997) Evidence that antipsychotic drugs are inverse agonists at D2 dopamine receptors. Br J Pharmacol 121:731–736.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Hall H,
    2. Halldin C,
    3. Dijkstra D,
    4. Wiltröm H,
    5. Wise LD,
    6. Purgsley TA,
    7. Sokoloff P,
    8. Pauli S,
    9. Farde L,
    10. Sedvall G
    (1996) Autoradiographic localisation of D3-dopamine receptors in the human brain using the selective D3-dopamine receptor agonist (+)-[3H]PD 128907. Psychopharmacology 128:240–247.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Herroelen L,
    2. De Backer J-P,
    3. Wilczak N,
    4. Flamez A,
    5. Vauquelin G,
    6. De Keyser J
    (1994) Autoradiographic distribution of D3-type dopamine receptors in human brain using [3H]-7-hydroxy-N,N-di-n-propyl-2-aminotetralin. Brain Res 648:222–228.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Hjorth S,
    2. Sharp T
    (1990) Mixed agonist/antagonist properties of NAN-190 at 5-HT1A receptors: Behavioural and in vivo brain microdialysis studies. Life Sci 46:955–963.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Hurley MJ,
    2. Stubbs CM,
    3. Jenner P,
    4. Marsden CD
    (1996) Dopamine D3 receptors are not involved in the induction of c-fos mRNA by neuroleptic drugs: Comparison of the dopamine D3 receptor antagonist GR 103,691 with typical and atypical neuroleptics. Eur J Pharmacol 318:283–293.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Kenakin T
    (1996) The classification of seven transmembrane receptors in recombinant expression systems. Pharmacol Rev 48:413–463.
    OpenUrlPubMed
  36. ↵
    1. Khroyan TV,
    2. Baker DA,
    3. Neisewander JL
    (1995) Dose-dependent effects of the D3-preferring agonist 7-OH-DPAT on motor behaviors and place conditioning. Psychopharmacology 122:351–357.
    OpenUrlCrossRefPubMed
  37. ↵
    1. Kling-Petersen T,
    2. Ljung E,
    3. Svensson K
    (1995) Effects on locomotor activity after local application of D3-preferring compounds in discrete areas of the rat brain. J Neural Transm 102:209–220.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Koeltzow TE,
    2. Xu M,
    3. Cooper DC,
    4. Hu XT,
    5. Tonegawa S,
    6. Wolf ME,
    7. White FJ
    (1998) Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice. J Neurosci 18:2231–2238.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Kulagowski JJ,
    2. Broughton HB,
    3. Curtis NR,
    4. Mawer IM,
    5. Ridgill MP,
    6. Baker R,
    7. Emms F,
    8. Freedman SB,
    9. Patel S,
    10. Ragan CI,
    11. Leeson PD
    (1996) 3-[[4-4-Chlorophenyl)piperazin-1-yl]-methyl]-1H-pyrrolo [2,3-b]pyridine: An antagonist with high affinity and selectivity for the human dopamine D4 receptor. J Med Chem 39:1941–1942.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Lajiness MEC,
    2. Chio CL,
    3. Huff RM
    (1993) D2 dopamine receptor stimulation of mitogenesis in transfected Chinese hamster ovary cells: Relationship to dopamine stimulation of tyrosine phosphorylations. J Pharmacol Exp Ther 267:1573–1581.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Landwehrmeyer B,
    2. Mengod G,
    3. Palacios JM
    (1993) Dopamine D3 receptor mRNA and binding sites in human brain. Mol Brain Res 18:187–192.
    OpenUrlPubMed
  42. ↵
    1. Larson ER,
    2. Ariano MA
    (1995) D3 and D2 dopamine receptors: Visualization of cellular expression patterns in motor and limbic structures. Synapse 20:325–337.
    OpenUrlCrossRefPubMed
  43. ↵
    1. Lejeune F,
    2. Audinot V,
    3. Gobert A,
    4. Rivet J-M,
    5. Spedding M,
    6. Millan MJ
    (1994) Clozapine inhibits serotonergic transmission by an action at α1-adrenoceptors not at 5-HT1A receptors. Eur J Pharmacol 260:79–83.
    OpenUrlCrossRefPubMed
  44. ↵
    1. Lejeune F,
    2. Millan MJ
    (1995) Activation of dopamine D3 autoreceptors inhibits firing of ventral tegmental dopaminergic neurones in vivo. Eur J Pharmacol 275:R7–R9.
    OpenUrlCrossRefPubMed
  45. ↵
    1. Le Moine C,
    2. Bloch B
    (1996) Expression of the D3 dopamine receptor in peptidergic neurons of the nucleus accumbens: Comparison with the D1 and D2 dopamine receptors. Neuroscience 73:131–143.
    OpenUrlCrossRefPubMed
  46. ↵
    1. Levant B
    (1997) The D3 dopamine receptor: Neurobiology and potential clinical relevance. Pharmacol Rev 49:231–252.
    OpenUrlAbstract/FREE Full Text
  47. ↵
    1. Levant B,
    2. Grigoriadis DE,
    3. DeSouza EB
    (1993) [3H]Quinpirole binding to putative D2 and D3 dopamine receptors in rat brain and pituitary gland: A quantitative autoradiographic study. J Pharmacol Exp Ther 264:991–1001.
    OpenUrlAbstract/FREE Full Text
  48. ↵
    1. Lévesque D
    (1996) Aminotetralin drugs and D3 receptor functions. Bioch Pharmacol 52:511–518.
    OpenUrlCrossRefPubMed
  49. ↵
    1. Lévesque D,
    2. Diaz J,
    3. Pilon C,
    4. Martres M-P,
    5. Giros B,
    6. Souil E,
    7. Schott D,
    8. Morgat J-L,
    9. Schwartz J-C,
    10. Sokoloff P
    (1992) Identification, characterization, and localization of the dopamine D3 receptor in rat brain using [3H]-7-hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc Natl Acad Sci 89:8155–8159.
    OpenUrlAbstract/FREE Full Text
  50. ↵
    1. McChesney R,
    2. Sealfon SC,
    3. Tsutsumi M,
    4. Dong KW,
    5. Roberts JL,
    6. Bancroft C
    (1991) Either isoform of the dopamine D2 receptor can mediate dopaminergic repression of the rat prolactin promoter. Mol Cell Endocrinology 79:R1–R7.
    OpenUrlCrossRefPubMed
  51. ↵
    1. McDonald WM,
    2. Sibley DR,
    3. Kilpatrick BF,
    4. Caron MG
    (1984) Dopaminergic inhibition of adenylate cyclase correlates with high affinity agonist binding to anterior pituitary D2 dopamine receptor. Mol Cell Endocrinol 36:201–209.
    OpenUrlCrossRefPubMed
  52. ↵
    1. Meador-Woodruff JH,
    2. Damask SP,
    3. Wang J,
    4. Haroutunian V,
    5. Davis KL,
    6. Watson SJ
    (1996) Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology 15:17–29.
    OpenUrlCrossRefPubMed
  53. ↵
    1. Merchant KM,
    2. Gill GS,
    3. Harris DW,
    4. Huff RM,
    5. Eaton MJ,
    6. Lookingland K,
    7. Lutzke BS,
    8. McCall RB,
    9. Piercey MF,
    10. Schreur PJKD,
    11. Sethy VH,
    12. Smith MW,
    13. Svensson KA,
    14. Tang AH,
    15. Vonvoigtlander PF,
    16. Tenbrink RE
    (1996) Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist. J Pharmacol Exp Ther 279:1392–1403.
    OpenUrlAbstract/FREE Full Text
  54. ↵
    1. Mercuri NB,
    2. Saiardi A,
    3. Bonci A,
    4. Picetti R,
    5. Calabresi P,
    6. Bernardi G,
    7. Borrelli E
    (1997) Loss of autoreceptor function in dopaminergic neurons from dopamine D2 receptor deficient mice. Neuroscience 79:323–327.
    OpenUrlCrossRefPubMed
  55. ↵
    1. Millan MJ,
    2. Audinot V,
    3. Rivet J-M,
    4. Gobert A,
    5. Vian J,
    6. Prost J-F,
    7. Spedding M,
    8. Peglion J-L
    (1994) S 14297, a novel selective ligand at cloned human dopamine D3 receptors, blocks 7-OH-DPAT-induced hypothermia in rats. Eur J Pharmacol 260:R3–R5.
    OpenUrlCrossRefPubMed
  56. ↵
    1. Millan MJ,
    2. Gressier H,
    3. Brocco M
    (1997) The dopamine D3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats. Eur J Pharmacol 321:R7–R9.
    OpenUrlCrossRefPubMed
  57. Millan MJ, Newman-Tancredi A, Brocco M, Gobert A, Lejeune F, Audinot V, Rivet JM, Schreiber R, Dekeyne A, Spedding M, Nicolas JP and Peglion JL (1998) S-18126 ({2-[4-(2,3-dihydrobenzo [1,4]dioxin-6-yl) piperazin-1-yl methyl] indan-2-yl}): a potent, selective and competitive antagonist at dopamine D4 receptors: Anin vitro and in vivo comparison to L-745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2,3b]pyridine) and raclopride. J Pharmacol Exp Ther, in press..
  58. ↵
    1. Millan MJ,
    2. Newman-Tancredi A,
    3. Audinot V,
    4. Brocco M,
    5. Gobert A,
    6. Rivet J-M,
    7. Peglion J-L
    (1996) S 18126, a novel, potent and selective antagonist at human (h) recombinant dopamine (DA) hD4 receptors (Abstract). Am Soc Neuroscience 22:1772.
  59. ↵
    1. Millan MJ,
    2. Peglion J-L,
    3. Vian J,
    4. Rivet J-M,
    5. Brocco M,
    6. Gobert A,
    7. Newman-Tancredi A,
    8. Dacquet C,
    9. Bervoets K,
    10. Girardon S,
    11. Jacques V,
    12. Chaput C,
    13. Audinot V
    (1995) Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297. I. Activation of postsynaptic D3 receptors mediates hypothermia while blockade of D2 receptors elicits prolactin secretion and catalepsy. J Pharmacol Exp Ther 275:885–898.
    OpenUrlAbstract/FREE Full Text
  60. ↵
    1. Momiyama T,
    2. Todo N,
    3. Sasa M
    (1993) A mechanism underlying dopamine D1 and D2 receptor-mediated inhibition of dopaminergic neurones in the ventral tegmental area in vitro. Br J Pharmacol 109:933–940.
    OpenUrlPubMed
  61. ↵
    1. Morris BJ,
    2. Newman-Tancredi A,
    3. Audinot V,
    4. Simpson CS,
    5. Millan MJ
    (1997) Induction of c-fos expression in cultured rat striatal neurons by activation of dopamine D3 receptors. Br J Pharmacol Proc 122:279P.
    OpenUrl
  62. ↵
    1. Murray PJ,
    2. Harrison LA,
    3. Johnson MR,
    4. Robertson GM,
    5. Scopes DIC,
    6. Bull DR,
    7. Graham EA,
    8. Hayes AG,
    9. Kilpatrick GJ,
    10. Den Daas I,
    11. Large C,
    12. Sheehan MJ,
    13. Stubbs CM,
    14. Turpin MP
    (1995) A novel series of arylpiperazines with high affinity and selectivity for the dopamine D3 receptor. Bioorganic Med Chem Lett 5:219–222.
  63. ↵
    1. Murray PJ,
    2. Helden RM,
    3. Johnson MR,
    4. Robertson GM,
    5. Scopes DIC,
    6. Stokes M,
    7. Wadman S,
    8. Whitehead JWF,
    9. Hayes AG,
    10. Kilpatrick GJ,
    11. Large C,
    12. Stubbs CM,
    13. Turpin MP
    (1996) Novel 6-substituted 2-aminotetralins with potent and selective affinity for the dopamine D3 receptor. Bioorganic Med Chem Lett 6:403–408.
    OpenUrlCrossRef
  64. ↵
    1. Murray AM,
    2. Ryoo H,
    3. Gurevich E,
    4. Joyce JN
    (1994) Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Proc Natl Acad Sci 91:11271–11272.
    OpenUrlAbstract/FREE Full Text
  65. ↵
    1. Newman-Tancredi A,
    2. Audinot V,
    3. Jacques V,
    4. Peglion J-L,
    5. Millan MJ
    (1995) [3H]-(+)-S 14297: A novel, selective radioligand at cloned human dopamine D3 receptors. Neuropharmacology 34:1693–1696.
    OpenUrlCrossRefPubMed
  66. ↵
    1. Nilsson CL,
    2. Ekman A,
    3. Hellstrand M,
    4. Eriksson E
    (1996) Inverse agonism at D2 receptors: Haloperidol-induced prolactin release from GH4C1 cells transfected with the human D2 receptor is antagonised by R(−)-n-propylanorapomorphine, raclopride and phenoxybenzamine. Neuropsychopharmacology 15:53–61.
    OpenUrlCrossRefPubMed
  67. ↵
    1. O’Hara CM,
    2. Uhland-Smih A,
    3. O’Malley KL,
    4. Todd RD
    (1996) Inhibition of dopamine synthesis by dopamine D2 and D3 but not D4 receptors. J Pharmacol Exp Ther 277:186–192.
    OpenUrlAbstract/FREE Full Text
  68. ↵
    1. Piercey MF,
    2. Moon MW,
    3. Sethly VH,
    4. Schreur PJKD,
    5. Smith MW,
    6. Tang AH,
    7. VonVoigtlander PF
    (1996) Pharmacology of U-91356A, an agonist for the dopamine D2 receptor subtype. Eur J Pharmacol 317:29–38.
    OpenUrlCrossRefPubMed
  69. ↵
    1. Richtand NM,
    2. Kelsoe JR,
    3. Segal DS,
    4. Kuczenski R
    (1995) Regional quantification of D1, D2 and D3 dopamine receptor mRNA in rat brain using a ribonuclease protection assay. Mol Brain Res 33:97–103.
    OpenUrlPubMed
  70. ↵
    1. Rivet J-M,
    2. Audinot V,
    3. Gobert A,
    4. Peglion J-L,
    5. Millan MJ
    (1994) Modulation of mesolimbic dopamine release by the selective dopamine D3 receptor antagonist, (+)-S 14297. Eur J Pharmacol 265:175–177.
    OpenUrlCrossRefPubMed
  71. ↵
    1. González-Mora JL,
    2. Borges R,
    3. Mas E
    1. Rivet J-M,
    2. Gobert A,
    3. Audinot V,
    4. Brocco M,
    5. Millan MJ
    (1996) Functional roles of dopamine D3 and D2 receptors: A comparison of PD 128,907, a preferential dopamine D3 agonist, to bromocriptine, a preferential dopamine D2 agonist, in Monitoring Molecules in Neuroscience, in Proceedings of the 6th Intern. Conf. on in vivo Methods, eds González-Mora JL, Borges R, Mas E pp 93–94.
  72. ↵
    1. Roberts DCS,
    2. Ranaldi R
    (1995) Effect of dopaminergic drugs on cocaine reinforcement. Clin Neuropharmacol 18:S84–S95.
    OpenUrl
  73. ↵
    1. Salmi P,
    2. Jimenez P,
    3. Ahlenius S
    (1993) Evidence for specific involvement of dopamine D1 and D2 receptors in the regulation of body temperature in the rat. Eur J Pharmacol 236:395–400.
    OpenUrlCrossRefPubMed
  74. ↵
    1. Sanger DJ,
    2. Depoortere R,
    3. Perrault G
    (1996) Evidence for a role for dopamine D3 receptors in the effects of dopamine agonists on operant behaviour in rats. Behav Pharmacol 7:477–482.
    OpenUrlPubMed
  75. ↵
    1. Sautel F,
    2. Griffon N,
    3. Lévesque D,
    4. Pilon C,
    5. Schwartz J-C,
    6. Sokoloff P
    (1995) A functional test identifies dopamine agonists selective for D3 versus D2 receptors. NeuroReport 6:329–332.
    OpenUrlPubMed
  76. ↵
    1. Sautel F,
    2. Griffon N,
    3. Sokoloff P,
    4. Schwartz J-C,
    5. Launay C,
    6. Simon P,
    7. Costentin J,
    8. Schoenfelder A,
    9. Garrido F,
    10. Mann A,
    11. Wermuth CG
    (1996) Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. J Pharmacol Exp Ther 275:1239–1246.
    OpenUrlAbstract/FREE Full Text
  77. ↵
    1. Seabrook GR,
    2. Patel S,
    3. Hutson PH,
    4. Ragan CI,
    5. Bristow LJ
    (1995) Functional relevance of dopamine receptors. Trends Pharmacol Sci 16:406–407.
    OpenUrlCrossRefPubMed
  78. ↵
    1. Sokoloff P,
    2. Andrieux M,
    3. Besançon R,
    4. Pilon C,
    5. Martres M-P,
    6. Giros B,
    7. Schwartz J-C
    (1992) Pharmacology of human dopamine D3 receptor expressed in mammalian cell line: Comparison with D2 receptor. Eur J Pharmacol 225:331–337.
    OpenUrlCrossRefPubMed
  79. ↵
    1. Sokoloff P,
    2. Schwartz J-C
    (1995) Novel dopamine receptors half a decade later. Trends Pharmacol Sci 16:270–275.
    OpenUrlCrossRefPubMed
  80. ↵
    1. Spealman RD
    (1996) Dopamine D3 receptor agonists partially reproduce the discriminative stimulus effects of cocaine in squirrel monkeys. J Pharmacol Exp Ther 278:1128–1137.
    OpenUrlAbstract/FREE Full Text
  81. ↵
    1. Strange PG
    (1993) New insights into dopamine receptors in the central nervous system. Neurochem Int 22:223–236.
    OpenUrlCrossRefPubMed
  82. ↵
    1. Surmeier DJ,
    2. Eberwine J,
    3. Wilson CJ,
    4. Cao Y,
    5. Stefani A,
    6. Kitai ST
    (1992) Dopamine receptor subtypes colocalize in rat striatonigral neurons. Proc Natl Acad Sci 89:10178–10182.
    OpenUrlAbstract/FREE Full Text
  83. ↵
    1. Svensson K,
    2. Carlsson A,
    3. Hugh RM,
    4. Kling-Petersen T,
    5. Waters N
    (1994) Behavioural and neurochemical data suggest functional differences between dopamine D2 and D3 receptors. Eur J Pharmacol 263:235–243.
    OpenUrlCrossRefPubMed
  84. ↵
    1. Tang L,
    2. Todd RD,
    3. Heller A,
    4. O’Malley KL
    (1994) Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblast and dopaminergic cell lines. J Pharmacol Exp Ther 268:495–502.
    OpenUrlAbstract/FREE Full Text
  85. ↵
    1. Tepper JM,
    2. Sun BC,
    3. Martin LP,
    4. Creese I
    (1997) Functional roles of dopamine D2 and D3 autoreceptors on nigrostriatal neurons analyzed by antisense knockdown in vivo. J Neurosci 17:2519–2530.
    OpenUrlAbstract/FREE Full Text
  86. ↵
    1. Van Vliet A,
    2. Tepper PG,
    3. Dijikstra D,
    4. Damsma G,
    5. Wikström H,
    6. Pugsley TA,
    7. Akunne HC,
    8. Heffner TG,
    9. Glase SA,
    10. Wise LD
    (1996) Affinity for dopamine D2, D3 and D4 receptors of 2-aminotetralins. Relevance of D2 agonist binding for determination of receptor subtype selectivity. J Med Chem 39:4233–4237.
    OpenUrlCrossRefPubMed
  87. ↵
    1. Waldemeier PC,
    2. Delini-Stula AA
    (1979) Serotonin-dopamine interactions in the nigrostriatal system. Eur J Pharmacol 55:363–373.
    OpenUrlCrossRefPubMed
  88. ↵
    1. Wallace DR,
    2. Mactutus CF,
    3. Booze RM
    (1996) Repeated intravenous cocaine administration: Locomotor activity and dopamine D2/D3 receptors. Synapse 23:152–163.
    OpenUrlCrossRefPubMed
  89. ↵
    1. Waters N,
    2. Hansson L,
    3. Löfberg L,
    4. Carlsson A
    (1994a) Intracerebral infusion of (+)-AJ 76 and (+)-UH 232: Effects on dopamine release and metabolism in vivo. Eur J Pharmacol 251:181–190.
    OpenUrlCrossRefPubMed
  90. ↵
    1. Waters N,
    2. Löfberg L,
    3. Haadsma-Svensson K,
    4. Sonesson C,
    5. Carlsson A
    (1994b) Differential effects of dopamine D2 and D3 receptor antagonists in regard to dopamine release, in vivo receptor displacement and behaviour. J Neural Transm 98:39–55.
    OpenUrlCrossRefPubMed
  91. ↵
    1. Waters N,
    2. Svensson K,
    3. Haadsma-Svensson SR,
    4. Smith MW,
    5. Carlsson A
    (1993) The dopamine D3-receptor: A postsynaptic receptor inhibitory on rat locomotor activity. J Neural Transm 94:11–19.
    OpenUrlCrossRefPubMed
  92. ↵
    1. Willner P
    (1983) Dopamine and depression. A review of recent evidence. III. The effects of antidepressant treatments. Brain Res Rev 6:237–246.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 287, Issue 1
1 Oct 1998
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A Comparative In Vitro and In VivoPharmacological Characterization of the Novel Dopamine D3Receptor Antagonists (+)-S 14297, Nafadotride, GR 103,691 and U 99194
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

A Comparative In Vitro and In VivoPharmacological Characterization of the Novel Dopamine D3Receptor Antagonists (+)-S 14297, Nafadotride, GR 103,691 and U 99194

Valérie Audinot, Adrian Newman-Tancredi, Alain Gobert, Jean-Michel Rivet, Mauricette Brocco, Françoise Lejeune, Laurence Gluck, Isabelle Desposte, Karin Bervoets, Anne Dekeyne and Mark J. Millan
Journal of Pharmacology and Experimental Therapeutics October 1, 1998, 287 (1) 187-197;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

A Comparative In Vitro and In VivoPharmacological Characterization of the Novel Dopamine D3Receptor Antagonists (+)-S 14297, Nafadotride, GR 103,691 and U 99194

Valérie Audinot, Adrian Newman-Tancredi, Alain Gobert, Jean-Michel Rivet, Mauricette Brocco, Françoise Lejeune, Laurence Gluck, Isabelle Desposte, Karin Bervoets, Anne Dekeyne and Mark J. Millan
Journal of Pharmacology and Experimental Therapeutics October 1, 1998, 287 (1) 187-197;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Material and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Meeting Report for the ASPET–Ray Fuller Symposium: Cellular Mechanisms and Novel Strategies for Pain Control
  • Antinociceptive Properties of Fenfluramine, a Serotonin Reuptake Inhibitor, in a Rat Model of Neuropathy
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics